OFELIA
BANIANDRÉS RODRÍGUEZ
Profesora asociada de Ciencias de la Salud
![Foto de Esteban](/img/nophoto.png)
Esteban
Daudén Tello
Esteban Daudén Tello-rekin lankidetzan egindako argitalpenak (16)
2024
-
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511
-
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice
Experimental Dermatology, Vol. 33, Núm. 8
-
Ustekinumab is effective and safe in the long-term treatment of erythrodermic psoriasis: Multicenter study in daily practice
JEADV Clinical Practice, Vol. 3, Núm. 2, pp. 604-610
2023
-
Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice
Journal of the European Academy of Dermatology and Venereology
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
2022
-
Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice
Journal of the European Academy of Dermatology and Venereology
2021
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
-
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain
Dermatology and Therapy, Vol. 11, Núm. 6, pp. 2207-2215
2020
-
A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg
Dermatologic Therapy, Vol. 33, Núm. 4
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
2019
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis
Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 70-75
2015
-
New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: A case-control study
British Journal of Dermatology
-
Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis
Journal of Immunology Research, Vol. 2015
-
The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis
Pharmacogenomics, Vol. 16, Núm. 15, pp. 1723-1731